Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gallium Ga-68 Gozetotide

FDA-approved product (solution, intravenous), marketed as Gallium Ga 68 Gozetotide, Gozellix, Illuccix and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gallium Ga-68 Gozetotide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neuroimaging measurement

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gallium Ga-68 Gozetotide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gallium Ga-68 Gozetotide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • 68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer

    NCT05134064 · start 2020-12-01

    Registered record
    Registry ID
    NCT05134064
    Conditions
    PET/CT; Prostate Specific Membrane Antigen; IMAGE
    Interventions
    total-body PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-01
    Completion
    2021-08-31
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPET/CT; Prostate Specific Membrane Antigen; IMAGE
    Interventiontotal-body PET/CT
    PhaseNot recorded
    Registry statusCompleted

  • PET/MRI to Stage Prostate Cancer Patients

    NCT06484361 · start 2020-09-09

    Registered record
    Registry ID
    NCT06484361
    Conditions
    Prostate Cancer
    Interventions
    68Ga-PSMA; 68Ga-RM2
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-09-09
    Completion
    2025-09-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention68Ga-PSMA; 68Ga-RM2
    PhasePhase 2
    Registry statusUnknown

  • PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer

    NCT04310540 · start 2020-06-05

    Registered record
    Registry ID
    NCT04310540
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Biopsy; Computed Tomography; Gallium Ga 68 Gozetotide; Magnetic Resonance Imaging; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2020-06-05
    Completion
    2023-11-02
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionBiopsy; Computed Tomography; Gallium Ga 68 Gozetotide; Magnetic Resonance Imaging +1 more
    PhaseEarly phase 1
    Registry statusCompleted

  • Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

    NCT04279561 · start 2020-04-16

    Registered record
    Registry ID
    NCT04279561
    Conditions
    Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Computed Tomography; Gallium Ga 68 Gozetotide; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-04-16
    Completion
    2022-09-15
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Prostate Cancer AJCC v8 +1 more
    InterventionComputed Tomography; Gallium Ga 68 Gozetotide; Positron Emission Tomography
    PhasePhase 1
    Registry statusTerminated

  • Combination of 68Ga-PSMA PET Data With Magnetic Resonance Spectroscopy Data (MRS) for Evaluating Prostate Cancer

    NCT04154280 · start 2020-04-10

    Registered record
    Registry ID
    NCT04154280
    Conditions
    Prostate Cancer
    Interventions
    PET/MR scan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-04-10
    Completion
    2022-04-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPET/MR scan
    PhaseNot applicable
    Registry statusUnknown

  • Using PSMA PET-CT as a Diagnostic Tool for Detection of Prostatic Cancer at an Early Stage

    NCT04116086 · start 2019-09-11

    Registered record
    Registry ID
    NCT04116086
    Conditions
    Prostate Cancer
    Interventions
    Prostate Biopsy Test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-09-11
    Completion
    2020-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionProstate Biopsy Test
    PhaseNot applicable
    Registry statusUnknown

  • Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

    NCT03762759 · start 2019-05-10

    Registered record
    Registry ID
    NCT03762759
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Computed Tomography; Fluciclovine F18; Gallium Ga68-labeled PSMA-11; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-05-10
    Completion
    2030-05-19
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionComputed Tomography; Fluciclovine F18; Gallium Ga68-labeled PSMA-11; Positron Emission Tomography
    PhasePhase 2
    Registry statusActive not recruiting

  • Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

    NCT03582774 · start 2018-07-12

    Registered record
    Registry ID
    NCT03582774
    Conditions
    Recurrent Prostate Carcinoma
    Interventions
    Best Practice; Computed Tomography; Gallium Ga 68-labeled PSMA-11; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2018-07-12
    Completion
    2028-07-12
    Enrolment
    193

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Prostate Carcinoma
    InterventionBest Practice; Computed Tomography; Gallium Ga 68-labeled PSMA-11; Positron Emission Tomography
    PhasePhase 3
    Registry statusActive not recruiting

  • 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

    NCT03490838 · start 2018-05-24

    Registered record
    Registry ID
    NCT03490838
    Conditions
    Prostatic Neoplasm
    Interventions
    177Lu-PSMA-R2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-05-24
    Completion
    2022-06-02
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasm
    Intervention177Lu-PSMA-R2
    PhasePhase 1
    Registry statusTerminated

  • 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

    NCT03490032 · start 2018-05-23

    Registered record
    Registry ID
    NCT03490032
    Conditions
    Prostate Cancer Metastatic
    Interventions
    [68Ga]-PSMA-R2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-05-23
    Completion
    2019-09-13
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    Intervention[68Ga]-PSMA-R2
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

    NCT03857087 · start 2018-04-02

    Registered record
    Registry ID
    NCT03857087
    Conditions
    Ovarian Carcinoma
    Interventions
    Gallium Ga 68-labeled PSMA-11; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-04-02
    Completion
    2022-06-30
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Carcinoma
    InterventionGallium Ga 68-labeled PSMA-11; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET)
    PhaseNot recorded
    Registry statusCompleted

  • Ga-68-PSMA-11 in High-risk Prostate Cancer

    NCT03362359 · start 2017-10-09

    Registered record
    Registry ID
    NCT03362359
    Conditions
    High-risk Prostate Cancer; Prostate Cancer; Prostate Cancer Metastatic; Lymphnode Metastasis
    Interventions
    Ga-68-PSMA-11
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-10-09
    Completion
    2020-07-06
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-risk Prostate Cancer; Prostate Cancer; Prostate Cancer Metastatic; Lymphnode Metastasis
    InterventionGa-68-PSMA-11
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRI

    NCT03223064 · start 2016-12-30

    Registered record
    Registry ID
    NCT03223064
    Conditions
    Prostate Cancer; Lymph Node Metastases
    Interventions
    Ferumoxtran-10 enhanced MRI; MRI contrast agent; 68Ga PSMA PET-CT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-12-30
    Completion
    2017-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Lymph Node Metastases
    InterventionFerumoxtran-10 enhanced MRI; MRI contrast agent; 68Ga PSMA PET-CT
    PhaseNot applicable
    Registry statusUnknown

  • Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

    NCT02810886 · start 2016-10

    Registered record
    Registry ID
    NCT02810886
    Conditions
    Prostate Cancers
    Interventions
    68Ga-(HBED-CC)-PSMA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2016-10
    Completion
    2017-01-20
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancers
    Intervention68Ga-(HBED-CC)-PSMA
    PhasePhase 2
    Registry statusWithdrawn

  • 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

    NCT02678351 · start 2016-04-18

    Registered record
    Registry ID
    NCT02678351
    Conditions
    Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
    Interventions
    68Ga-PSMA-11; Magnetic resonance imaging (MRI); Positron Emission Tomography (PET)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-04-18
    Completion
    2021-12
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
    Intervention68Ga-PSMA-11; Magnetic resonance imaging (MRI); Positron Emission Tomography (PET)
    PhasePhase 2 / Phase 3
    Registry statusCompleted